Project Grant K08CA304485
Award Date 8/17/26
Completion Date 7/31/31
Dollars Obligated $264K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute awarded The Children's Hospital Of Philadelphia $744,511 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize hematopoietic stem and progenitor cell-like (HSPC-like) blasts in high-risk acute leukemias and identify therapeutic vulnerabilities in these treatment-resistant leukemic populations. The research investigates molecular characteristics and clinical implications of HSPC-like blasts across major high-risk leukemia...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $181,610 on September 1, 2026, to develop and deploy computational methods for creating novel immunotherapies targeting neuroblastoma in children under the Cancer Treatment Research program (CFDA 93.395). The funded work centers on bioinformatics pipeline development and analysis of proteogenomic data to identify new immunotherapeutic targets for pediatric cancer. Under the leadership of Dr. John Maris and...
- The National Cancer Institute awarded The Regents Of The University Of Colorado (University of Colorado-Denver) $706,866 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize FLT3-targeted and menin-modulated chimeric antigen receptor (CAR) T cell immunotherapies against KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) and prevent treatment-resistant relapse and lineage switch to acute myeloid leukemia. The recipient will develop best-in-class...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $737,082 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop bioinspired virus-like nanovaccines that boost chimeric antigen receptor (CAR) T cell and endogenous T cell responses against solid tumors with antigen heterogeneity. The recipient will develop an autologous tumor cell membrane-coated dual CAR and endogenous T cell boosting virus-like nanoparticle vaccine (DTVLP-VAX) to...
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $737,023 under the Cancer Treatment Research program (CFDA 93.395) on July 23, 2026, to develop and evaluate CD19-CAR T cell therapy combined with TCR alpha/beta–depleted haploidentical hematopoietic cell transplantation for pediatric patients with relapsed or refractory CD19+ acute lymphoblastic leukemia and lymphoma. The research aims to minimize relapse risk and graft-versus-host disease while eliminating total...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia Research Institute $276,545 on June 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop genomic risk prediction models for T-cell malignancies. The recipient will identify high-risk genomic features associated with relapse and death in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) stratified by genetic ancestry, then develop and validate risk prediction...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $172,889 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and optimize chimeric antigen receptor (CAR) T-cell therapies for acute myeloid leukemia (AML). The funded research applies structure-guided protein evolution to improve natural ligand-based CAR-T therapies targeting CD70 in AML. The project uses computational deep learning algorithms and high-throughput...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $738,666 on August 4, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer CD19 mimotopes for enhancing and repurposing CD19-CAR T cell therapy against hematological malignancies and solid tumors. The recipient will develop a high-affinity CD19 mimotope identified through yeast surface display screening to pair with existing CD19-CAR T products. The linear mimotope, a 10 amino acid peptide, is...
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...
- The National Cancer Institute awarded The Trustees of the University of Pennsylvania $434,969 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate type I interferon response and differentiation in FLT3-inhibitor persistent acute myeloid leukemia. The funded research develops genetically engineered mouse models of acute myeloid leukemia with inducible and reversible FLT3 mutations to understand cellular mechanisms that maintain FLT3-mutant clone persistence...